Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical rhGM-CSF for difficult-to-heal venous leg ulcers
2019-001483-30Phase 2Terminated
- Sponsor
- Reponex Pharmaceuticals
- Start
- Feb 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in stasis ulcer comparing Repogel plus standard care with Placebo plus standard care (2 arms). Primary endpoint: Proportion of patients with at least 40% ulcer area reduction at 4 weeks. Started Feb 2020; status: terminated.
02
Drugs
Repogel
03
Conditions
stasis ulcer
Beyond the preview
Go deeper on 2019-001483-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001483-30.